Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.
Academic Article
Overview
abstract
The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.
